In terms of provisions of Regulation 30 (read with Part A of Schedule III) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), this ....

Revenue declinedNegative operating cash flowResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.9%Reaction day

₹58.00

prior close

₹60.10

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.2%-2.1% vs market

Pharmaceuticals peers, median of 150sector+1.0%-1.8% vs sector

On the reaction day the stock moved 2.1 pts less than Nifty Microcap 250 and 1.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

-0.2

15m

-0.2

30m

-0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.9+1.2-2.1+1.0-1.8

Next day

-1.7+0.1-1.8-0.2-1.6

-6.6+0.9-7.5+0.6-7.3

-2.0+0.8-2.8+0.2-2.2

+1.7+1.4+0.3+0.1+1.6

+3.4+2.0+1.4+0.5+2.9

+8.3+2.3+6.0+1.5+6.8

15d

+3.6+5.2-1.5+1.4+2.2

-11.8+1.6-13.3-1.4-10.3

-7.2+7.7-14.9+3.7-11.0

-27.2+4.0-31.2-0.2-27.0

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 150Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Colinz Laboratories' board, meeting on 16th May 2025, approved the audited standalone financial results for the quarter and year ended 31st March 2025. Revenue from operations fell to ₹652.77 lakhs in FY25 from ₹702.96 lakhs in FY24, a decline of about 7%. Net profit for the year edged up marginally to ₹49.66 lakhs from ₹48.67 lakhs, with EPS of ₹1.97 (vs ₹1.93). Statutory auditors Vora & Associates issued an unqualified (unmodified) opinion on the results. The board also approved the appointment of an Additional Director to hold office until the next AGM. Notably, operating cash flow turned sharply negative at -₹145.37 lakhs versus +₹103.47 lakhs last year, largely due to a spike in other current assets.

Likely market impact

Mixed signals for shareholders: revenue continues to shrink year-on-year, but profits held steady, and the clean audit opinion is a positive. However, the sharp swing to negative operating cash flow and the dip in revenue may concern investors looking at underlying business momentum and liquidity.